PEP-RT
MetabolicPeptide RT
Overview
PEP-RT is a designation used by certain research peptide vendors. Based on vendor naming conventions in which "PEP" denotes a proprietary peptide formulation and "RT" likely refers to retatrutide (LY3437943), this designation most probably refers to a research-grade retatrutide analog, variant, or impure preparation.
**No published peer-reviewed research exists for PEP-RT as a named compound.** No molecular formula, sequence, mechanism, or safety data has been publicly disclosed for this specific vendor designation. It cannot be verified whether PEP-RT is chemically equivalent to, a structural variant of, or merely inspired by the Eli Lilly clinical compound retatrutide.
Mechanism of Action
If PEP-RT is retatrutide-adjacent, the presumed mechanism would involve triple receptor agonism at the GLP-1 receptor, GIP receptor, and glucagon receptor — the same triple-agonist mechanism that makes retatrutide one of the most efficacious investigational weight-loss agents in clinical trials (demonstrating up to 24% body weight reduction in Phase 2). However, without sequence confirmation and pharmacological characterization, this attribution is speculative.
True retatrutide is an Eli Lilly proprietary compound protected by patents; any "RT" analog from a research vendor would represent a structurally distinct compound with unknown similarity in pharmacological profile.
Research Dosing
PEP-RT appears to be a vendor-specific designation. Based on naming conventions, 'RT' likely denotes a retatrutide-adjacent or -analog compound. Retatrutide is a GLP-1/GIP/glucagon triple agonist developed by Eli Lilly. No clinical or pharmacological data has been published for PEP-RT as a named compound.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.